Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback